Procollagen C-protease enhancer protein promotes glioma growth by activating ERK signaling.

IF 1.4 4区医学 Q4 ONCOLOGY Asia-Pacific journal of clinical oncology Pub Date : 2024-10-15 DOI:10.1111/ajco.14127

Zhenchao Ma, Daxing Huang, Lixin Ru, Ming Chen

{"title":"Procollagen C-protease enhancer protein promotes glioma growth by activating ERK signaling.","authors":"Zhenchao Ma, Daxing Huang, Lixin Ru, Ming Chen","doi":"10.1111/ajco.14127","DOIUrl":null,"url":null,"abstract":"Background: Procollagen C-proteinase enhancer (PCOLCE) promotes tumor progression in multiple cancers. However, the specific role of PCOLCE in gliomas remains enigmatic. In this study, we focused on analyzing PCOLCE expression and its correlation with clinicopathological parameters in glioma specimens; moreover, we explored the effects of PCOLCE in glioma proliferation in vitro and in vivo.Methods: A tissue microarray containing 159 human glioma specimens was pressed to explore the correlation between PCOLCE expression and the survival of glioma patients. Cell Counting Kit-8 (CCK8), colony formation, and immunoblot assays were used to detect the role of PCOLCE on cell proliferation in glioma. Furthermore, the in vivo role of PCOLCE was investigated using a subcutaneous glioma xenograft model.Results: The expression of PCOLCE was higher in grade III and IV gliomas than in grade I and II gliomas. High PCOLCE expression was related to a remarkably worse prognosis in glioma patients. Additionally, PCOLCE downregulation impeded glioma cell proliferation. Furthermore, PCOLCE knockdown markedly abrogated p-ERK expression in glioma cells, whereas, it negligibly influenced p38 and JNK signaling.Conclusions: These results indicate that PCOLCE is a feasible prognostic biomarker for glioma, and PCOLCE-induced activation of ERK signaling may be a pro-growth mechanism in glioma cells.","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia-Pacific journal of clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ajco.14127","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Procollagen C-proteinase enhancer (PCOLCE) promotes tumor progression in multiple cancers. However, the specific role of PCOLCE in gliomas remains enigmatic. In this study, we focused on analyzing PCOLCE expression and its correlation with clinicopathological parameters in glioma specimens; moreover, we explored the effects of PCOLCE in glioma proliferation in vitro and in vivo.

Methods: A tissue microarray containing 159 human glioma specimens was pressed to explore the correlation between PCOLCE expression and the survival of glioma patients. Cell Counting Kit-8 (CCK8), colony formation, and immunoblot assays were used to detect the role of PCOLCE on cell proliferation in glioma. Furthermore, the in vivo role of PCOLCE was investigated using a subcutaneous glioma xenograft model.

Results: The expression of PCOLCE was higher in grade III and IV gliomas than in grade I and II gliomas. High PCOLCE expression was related to a remarkably worse prognosis in glioma patients. Additionally, PCOLCE downregulation impeded glioma cell proliferation. Furthermore, PCOLCE knockdown markedly abrogated p-ERK expression in glioma cells, whereas, it negligibly influenced p38 and JNK signaling.

Conclusions: These results indicate that PCOLCE is a feasible prognostic biomarker for glioma, and PCOLCE-induced activation of ERK signaling may be a pro-growth mechanism in glioma cells.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Procollagen C蛋白酶增强蛋白通过激活ERK信号促进胶质瘤生长。

背景：Procollagen C-蛋白酶增强子（PCOLCE）可促进多种癌症的肿瘤进展。然而，PCOLCE 在胶质瘤中的具体作用仍是一个谜。在本研究中，我们重点分析了胶质瘤标本中 PCOLCE 的表达及其与临床病理参数的相关性；此外，我们还探讨了 PCOLCE 在体外和体内对胶质瘤增殖的影响：方法：压制了包含 159 例人类胶质瘤标本的组织芯片，以探讨 PCOLCE 表达与胶质瘤患者生存之间的相关性。使用细胞计数试剂盒-8（CCK8）、菌落形成和免疫印迹试验检测 PCOLCE 对胶质瘤细胞增殖的作用。此外，还利用皮下胶质瘤异种移植模型研究了PCOLCE在体内的作用：结果：PCOLCE在III级和IV级胶质瘤中的表达高于I级和II级胶质瘤。PCOLCE的高表达与胶质瘤患者的预后明显恶化有关。此外，PCOLCE的下调会阻碍胶质瘤细胞的增殖。此外，PCOLCE基因敲除可显著降低胶质瘤细胞中p-ERK的表达，而对p38和JNK信号转导的影响则微乎其微：这些结果表明，PCOLCE 是一种可行的胶质瘤预后生物标志物，PCOLCE 诱导的 ERK 信号激活可能是胶质瘤细胞的一种促生长机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Asia-Pacific journal of clinical oncology 医学-肿瘤学

CiteScore

3.40

自引率

0.00%

发文量

175

审稿时长

6-12 weeks

期刊介绍： Asia–Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia–Pacific region in relation to cancer treatment and care. The Journal is ideally positioned to receive publications that deal with diversity in cancer behavior, management and outcome related to ethnic, cultural, economic and other differences between populations. In addition to original articles, the Journal publishes reviews, editorials, letters to the Editor and short communications. Case reports are generally not considered for publication, only exceptional papers in which Editors find extraordinary oncological value may be considered for review. The Journal encourages clinical studies, particularly prospectively designed clinical trials.